GYRE (GYRE) COO Ye exercises options and sells 28,680 shares in May

Rhea-AI Filing Summary

GYRE THERAPEUTICS, INC. Chief Operating Officer Weiguo Ye reported a small exercise-and-sell pattern over two days. On May 14 and 15, 2026, he exercised stock options to acquire a total of 28,680 shares of common stock at $0.75 per share and sold the same number of shares in open-market transactions, at weighted average prices of $6.91 and $6.65, respectively, across multiple trades.

After these transactions, Ye directly owns 700,000 shares of common stock. All options involved were fully vested, and the sales were executed across price ranges disclosed through weighted-average pricing footnotes.

Insider Trade Summary

Net Seller: 28,680 shares ($194,773)

Net Sell 6 txns

Insider Ye Weiguo

Role Chief Operating Officer

Sold 28,680 shs ($195K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	13,100	$0.00	--
Exercise	Common Stock	13,100	$0.75	$10K
Sale	Common Stock	13,100	$6.65	$87K
Exercise	Stock Option (Right to Buy)	15,580	$0.00	--
Exercise	Common Stock	15,580	$0.75	$12K
Sale	Common Stock	15,580	$6.91	$108K

Holdings After Transaction: Stock Option (Right to Buy) — 936,435 shares (Direct, null); Common Stock — 713,100 shares (Direct, null)

Footnotes (1)

1. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.8326 to $7.28. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.58 to $6.85. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. These options are vested in full.

Key Figures

Shares sold: 28,680 shares Options exercised: 28,680 shares Exercise price: $0.75 per share +4 more

7 metrics

Shares sold 28,680 shares Total open-market sales on May 14–15, 2026

Options exercised 28,680 shares Total shares acquired via option exercise

Exercise price $0.75 per share Stock option exercise price for common stock

Weighted average sale price (May 14) $6.91 per share 15,580 shares sold, prices from $6.8326 to $7.28

Weighted average sale price (May 15) $6.65 per share 13,100 shares sold, prices from $6.58 to $6.85

Post-transaction holdings 700,000 shares Common stock directly owned after transactions

Option expiration October 31, 2030 Expiration date for exercised stock options

Key Terms

open-market sale, derivative security, weighted average sale price, Stock Option (Right to Buy), +1 more

5 terms

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

weighted average sale price financial

"The price reported represents the weighted average sale price per share."

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

vested in full financial

"These options are vested in full."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ye Weiguo

(Last) (First) (Middle)

C/O GYRE THERAPEUTICS, INC.

12730 HIGH BLUFF DRIVE, SUITE 250

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GYRE THERAPEUTICS, INC. [ GYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/14/2026		M		15,580	A	$0.75	715,580	D
Common Stock	05/14/2026		S		15,580	D	$6.91(1)	700,000	D
Common Stock	05/15/2026		M		13,100	A	$0.75	713,100	D
Common Stock	05/15/2026		S		13,100	D	$6.65(2)	700,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.75	05/14/2026		M			15,580	(3)	10/31/2030	Common Stock	15,580	$0	949,535	D
Stock Option (Right to Buy)	$0.75	05/15/2026		M			13,100	(3)	10/31/2030	Common Stock	13,100	$0	936,435	D

Explanation of Responses:

1. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.8326 to $7.28. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.58 to $6.85. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

3. These options are vested in full.

	/s/ Weiguo Ye	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did GYRE COO Weiguo Ye report on this Form 4?

Weiguo Ye reported option exercises and related share sales. He exercised stock options for 28,680 GYRE common shares at $0.75 and sold the same number of shares in open-market trades on May 14 and 15, 2026, at weighted average prices above $6.50.

How many GYRE shares did COO Weiguo Ye sell and at what prices?

Ye sold 28,680 GYRE common shares in total. He sold 15,580 shares at a weighted average price of $6.91 and 13,100 shares at a weighted average price of $6.65, with each day’s sales executed across disclosed price ranges.

What was the option exercise price for Weiguo Ye’s GYRE stock options?

The exercised GYRE stock options had a $0.75 exercise price. On both May 14 and 15, 2026, Ye exercised fully vested stock options to acquire 15,580 and 13,100 common shares, respectively, each at $0.75 per share before selling the acquired stock.

How many GYRE THERAPEUTICS shares does COO Weiguo Ye hold after these trades?

After the reported transactions, Ye holds 700,000 GYRE shares. This post-transaction figure reflects his direct ownership of common stock following the exercise of 28,680 options and matched open-market sales on May 14 and 15, 2026.

Were GYRE COO Weiguo Ye’s stock options fully vested before exercise?

Yes, the exercised GYRE stock options were fully vested. A Form 4 footnote states that the options exercised on May 14 and 15, 2026 are “vested in full,” indicating they were completely earned and exercisable at the time of the transactions.

What price ranges applied to the GYRE share sales reported by Weiguo Ye?

The GYRE share sales were executed across price ranges. One sale day used prices from $6.8326 to $7.28, and the other from $6.58 to $6.85. Weighted average sale prices of $6.91 and $6.65 were reported for Form 4 disclosure.